Aspen FY26 normalised headline EPS rises 22% to 801.5 cents; revenue falls 1% to R 34.87 billion

• Aspen reported FY 2026 operating profit of ZAR 763 million, swinging from an operating loss of ZAR 790 million a year earlier.
• Headline earnings per share fell 20% to 630 cents, while earnings per share turned positive at 596 cents from a loss a year earlier.
• Normalised EBITDA rose 10% to ZAR 7.7 billion on flat revenue of ZAR 34.87 billion, diluted by a stronger rand.
• Commercial Pharmaceuticals revenue increased 3% to ZAR 25.41 billion on strong Mounjaro demand in South Africa; Manufacturing revenue dropped 11% to ZAR 9.47 billion.
• A gross dividend of 232 cents a share was declared, up 10%, payable Oct. 12.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspen Pharmacare Holdings Ltd. published the original content used to generate this news brief via SENS, the regulatory disclosure system operated by the Johannesburg Securities Exchange (JSE) (Ref. ID: S602535), on September 02, 2026, and is solely responsible for the information contained therein.